Kuros reports first profitable half-year with 45% growth

Swiss biotech company Kuros said on Monday it achieved its first profitable half-year, with revenue rising 45% in the first six months of 2026. The company attributed the growth to increased demand for its proprietary drug delivery platform, which has expanded its commercial partnerships in Europe and North America.

Kuros did not disclose specific revenue figures in its preliminary results, but said the platform’s adoption by pharmaceutical clients accelerated in the first half of the year. The company, which specializes in transdermal and intradermal drug delivery systems, has been expanding its manufacturing capacity to meet rising orders.

The firm highlighted that its first profitable half-year marks a significant milestone in its commercialization strategy, following years of investment in research and development. Kuros added that it expects continued growth in the second half of 2026, supported by existing contracts and new agreements under negotiation.

Shares of Kuros were not listed on a major exchange as of the time of reporting, and the company did not provide forward guidance in its update.